SynthesisJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine2025
Ultrasound-Guided Triamcinolone Injections for Hidradenitis Suppurativa Lesions: A Systematic Review and Meta-Analysis.
Synthesis in Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the role of ultrasound (US) guidance in intralesional triamcinolone (TAC) injections for hidradenitis suppurativa (HS) lesions and assess its impact on injection technique, clinical response rates, and patient-reported outcomes.
methodsWe conducted a systematic review of PubMed, Embase, and Cochrane databases from inception through October 2024. Studies that reported outcomes of US-guided TAC injections in patients with HS lesions (nodules, abscesses, or tunnels) were included. Data extraction included study design, lesion type, TAC concentration used, injection technique, clinical outcomes, and adverse events. Meta-analysis was performed to evaluate pooled clinical response rates, complete healing rates, and pain reduction. The protocol was registered on PROSPERO (CRD42024596593).
resultsSix studies encompassing 313 patients and 527 lesions were included. The pooled clinical response rate was 80.5% across all lesion types, with highest rates observed for abscesses (96.4%) and nodules (93.4%). Complete clinical healing was achieved in 69.8% of lesions. Meta-analysis of pain outcomes from 3 studies demonstrated a significant reduction in mean pain scores (standardized mean difference: -0.57; 95% CI: [-0.76, -0.37]; P = .0013). Adverse events were rare (5.4%) and no severe complications were reported.
conclusionsUS-guided TAC injections are a safe and potentially effective approach to treating HS lesions, particularly for complex or deep lesions. While preliminary data are promising, further randomized controlled studies are needed to directly compare outcomes with non-US-guided injections and to establish standardized protocols for injection technique.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.